ondansetron sold brand name zofran among others medication used prevent nausea vomiting caused cancer chemotherapy radiation therapy also effective treating given orally mouth intramuscularly injection muscle intravenously injection common side effects include diarrhea constipation headache sleepiness serious side effects include qt prolongation severe allergic appears safe pregnancy well studied serotonin receptor effect dopamine receptors muscarinic ondansetron patented approved medical use world health organizations list essential available generic commonly prescribed medication united states million ondansetron indicated prevention chemotherapyinduced nausea vomiting postoperative nausea ondansetron used offlabel treat morning sickness hyperemesis gravidarum pregnancy typically used antinausea drugs appears low risk harm baby use pregnancy though may increase heart problems among ondansetron one several antiemetic drugs used vomiting phase cyclic vomiting trials emergency department settings support use ondansetron reduce vomiting associated gastroenteritis retrospective review found used commonly purpose administered cases use reduced hospital admissions also associated higher rates return visits emergency department furthermore people initially received ondansetron likely admitted return visit people received drug however effect may simply due agent used frequently people present severe illness use found mask serious one study patients ibsd variant ondansetron showed statistically significant effect stool consistency bloating nonetheless antinociceptive ondansetron rarely studied people years age little data available guide dosage three open noncomparative studies conducted assess safety efficacy ondansetron children receiving variety chemotherapy regimens ondansetron well tolerated none patients experienced extrapyramidal headache common adverse review use postoperative nausea vomiting found every people treated one would experience headache could constipation diarrhea dizziness commonly reported side broken hepatic cytochrome system little effect metabolism drugs broken system anecdotally ototoxicity also reported injected use ondansetron associated prolongation qt interval lead potentially fatal heart rhythm known torsades de pointes although may happen person formulation risk salient injectable intravenous form drug increases dose risk also higher people taking medicines prolong qt interval well people congenital long qt syndrome congestive heart failure andor bradyarrhythmias single doses injectable ondansetron exceed mg one time oral dosing recommendations remain intact including recommendation single oral dose indicated electrolyte imbalances corrected use injectable ondansetron people cautioned seek immediate medical care symptoms irregular heartbeatpalpitations shortness breath dizziness fainting occur taking specific treatment available ondansetron overdose people managed supportive measures antidote ondansetron ondansetron highly selective serotonin receptor antagonist low affinity dopamine receptors receptors present peripherally vagal nerve terminals centrally chemoreceptor trigger zone area postrema medulla serotonin released enterochromaffin cells small intestine response chemotherapeutic agents may stimulate vagal afferents via receptors initiate vomiting reflex thought ondansetrons antiemetic action mediated mostly via antagonism vagal afferents minor contribution antagonism central ondansetron may degree peripheral selectivity due binding pglycoprotein efflux brain ondansetron marketed brand name zofran developed glaxosmithkline london granted us patent protection september received use patent june approved us fda january granted another divisional patent november finally owing glaxosmithklines research pediatric use ondansetrons patent protection extended december final year patent zofran become highestselling brandname drug united states sales billion first months first generic versions approved us fda december marketing approval granted teva pharmaceuticals usa sicor university s√£o paulo biolab granted patent orodispersible form ondansetron subject metaanalysis case study published british medical journal researchers examined trials people receiving ondansetron published september intravenous ondansetron mg versus placebo investigated reports three reports duplicated total six times number needed treat nnt prevent vomiting within hours confidence interval nonduplicated reports three duplicated reports nnt significantly lower reports combined apparent nnt improved inclusion duplicate reports led overestimation ondansetrons antiemetic addition authors found covert duplication reports ondansetron easy detect lack crossreferencing papers reports containing duplicate findings cited eight reviews analysis subject editorial journal american medical association ondansetron generic drug available many countries many brand httpsenwikipediaorgwikiondansetron